ISRCTN90744784
Completed
Not Applicable
Evaluation of humoral immune response induced by a supplemental dose of inactivated poliovirus vaccine (IPV) administered intradermally or intramuscularly versus a dose of monovalent type 1 oral poliovirus vaccine
Panacea Biotec Limited (India)0 sites1,000 target enrollmentNovember 26, 2008
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Panacea Biotec Limited (India)
- Enrollment
- 1000
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Healthy children in the target group (6 \- 9 months at baseline, either sex)
- •2\. Resident in Moradabad district, Uttar Pradesh, India
Exclusion Criteria
- •Children with chronic illness
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
CIMAvax-EGF in different maintenance schemeson small cell lung cancerNSCLCCarcinoma, Non-Small-Cell LungCarcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract DiseasesRPCEC00000368Center of Molecular Immunology (CIM)42
Not yet recruiting
Phase 3
Study of immunity to flu vaccine.CTRI/2021/11/037859Christian Medical College Vellore
Completed
Not Applicable
Pneumococcal conjugate vaccine trial: PNEUVAC TRIAISRCTN54494731niversity of Liverpool (UK)320
Active, not recruiting
Phase 1
Evaluation of immunological response following a revaccination with a non-conjugated pneumococcal vaccine boosted or not by a conjugated pneumococcal vaccine in splenectomised patients (SPLENEVAC-2)Asplenic patients at risk for invasive pneumococcal diseasesMedDRA version: 20.0Level: PTClassification code 10041642Term: SplenectomySystem Organ Class: 10042613 - Surgical and medical proceduresTherapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2018-003068-29-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)56
Completed
Not Applicable
Assessment of the humoral immune response and safety of reduced doses of influenza vaccine administered intradermally compared to intramuscular administratioInfluenzaInfections and InfestationsISRCTN33950739Berna Biotech AG, Crucell Company (Switzerland)275